Loading...
  • apheresis
  • The median time to apheresis (11 vs. 12 days) and the median CD34 content of stem cell harvest (8.3 vs. 7.6 million CD34 cells per kg bodyweight) did not differ significantly between both groups. (springermedizin.de)
  • On day 5, daily apheresis started and was continued for up to 4 days, or until ≥ 5 × 10 6 CD34+ cells/kg was collected. (springer.com)
  • In the GP arm, 9/16 patients (56.3%) achieved collection of ≥ 5 × 10 6 CD34+ cells/kg in ≤ 4 days of apheresis, while 1/16 patient (6.3%) achieved this target in the G arm. (springer.com)
  • Results of some clinical trials indicate that plerixafor in addition to granulocyte colony-stimulating factors (G-CSF) compared to G-CSF only could lead to an increased mobilisation and release of CD34-positive cells, facilitating effective apheresis. (uzh.ch)
  • Clinical
  • Clinical signs of CRS correlate with T-cell activation and high levels of cytokines, including interleukin 6 (IL-6). (medscape.com)
  • This pilot clinical trial studies cyclodextrin-based nanopharmaceutical CRLX101 in treating patients with advanced or metastatic stomach, gastroesophageal, or esophageal cancer that has progressed through at least one prior regimen of chemotherapy and cannot be removed by surgery. (clinicaltrials.gov)
  • disease
  • National Comprehensive Cancer Center guidelines suggest that screening with bone scans or abdominal imaging should be optional for patients with stage IIA and IIB disease and recommended for patients with stage III or greater disease. (cancernetwork.com)
  • In a review of the literature, bone scans detected skeletal metastases in 0.5%, 2.4%, and 8.3% of women with stage I, II, and III disease. (cancernetwork.com)
  • monoclonal
  • Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. (clinicaltrials.gov)